Gilead Sciences stock was on its way down Tuesday after releasing data from a recent Phase 3 clinical trial.
The recent STELLAR-4 Phase 3 clinical trial was for Gilead Sciences’ (NASDAQ:GILD) selonsertib to treat patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH). Unfortunately, selonsertib was unable to meet the primary endpoint for the clinical trial.
The blow to Gilead Sciences stock is that selonsertib was unable to reach a “≥ 1-stage histologic improvement in fibrosis without worsening of NASH.” This is based on the NASH Clinical Research Network’s classification.
The study included a total of 877 patients. Of these patients, 14.4% on the 18 mg dose and 12.5% on the 6 mg dose did see improvements without worsening NASH. In comparison, 12.8% of patients on a placebo also saw improvements without worsening NASH.
“Gilead has a long-term commitment and proven track record of addressing significant challenges in the field of liver diseases,” John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development at Gilead, said in a statement. “Data from this large study of patients with compensated cirrhosis due to NASH, including the extensive set of biomarkers collected, will further advance our understanding of the disease and inform our broader NASH development programs.”
Gilead Sciences says that it is now waiting for the results from its STELLAR-3 Phase 3 clinical trial. It also has a Phase 2 ATLAS clinical trial going on. Both of these clinical trials are using selonsertib.
GILD stock was down 3% as of Tuesday afternoon.
As of this writing, William White did not hold a position in any of the aforementioned securities.
